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Neuropsychiatric diseases such as schizophrenia and bipolar illness alter the structure and
function of distributed neural networks. Functional neuroimaging tools have evolved suffi-
ciently to reliably detect system-level disturbances in neural networks.This review focuses
on recent findings in schizophrenia and bipolar illness using resting-state neuroimaging,
an advantageous approach for biomarker development given its ease of data collection
and lack of task-based confounds. These benefits notwithstanding, neuroimaging does
not yet allow the evaluation of individual neurons within local circuits, where pharmaco-
logical treatments ultimately exert their effects. This limitation constitutes an important
obstacle in translating findings from animal research to humans and from healthy humans
to patient populations. Integrating new neuroscientific tools may help to bridge some of
these gaps. We specifically discuss two complementary approaches. The first is phar-
macological manipulations in healthy volunteers, which transiently mimic some cardinal
features of psychiatric conditions. We specifically focus on recent neuroimaging studies
using the NMDA receptor antagonist, ketamine, to probe glutamate synaptic dysfunction
associated with schizophrenia. Second, we discuss the combination of human pharmaco-
logical imaging with biophysically informed computational models developed to guide the
interpretation of functional imaging studies and to inform the development of pathophysi-
ologic hypotheses. To illustrate this approach, we review clinical investigations in addition
to recent findings of how computational modeling has guided inferences drawn from our
studies involving ketamine administration to healthy subjects.Thus, this review asserts that
linking experimental studies in humans with computational models will advance to effort
to bridge cellular, systems, and clinical neuroscience approaches to psychiatric disorders.
Keywords: schizophrenia, pharmacology, functional connectivity, computational modeling, thalamus, NMDA
receptors, glutamate
INTRODUCTION
The human brain is a complex, dynamic system with computa-
tions occurring at several levels of organization, from individual
synapses to networks that span multiple brain regions. These
large-scale neural systems ultimately produce complex behaviors
that are profoundly altered in the context of psychotropic drug
administration or neuropsychiatric disease.
One example is schizophrenia – a common, multi-faceted, and
heterogeneous neuropsychiatric syndrome (1) associated with dis-
turbances in perception (2), belief (3), emotion (4), and cognition
(5). A number of theoretical models of schizophrenia suggest
that the clinical features of this disorder emerge from distur-
bances in neural connectivity and deficits in synaptic plasticity
(6). Progress in explicating the pathophysiology of schizophre-
nia has been slowed by our limited understanding of the neu-
robiology of schizophrenia, shortcomings of animal models for
this disorder, and the challenge of translating basic and clini-
cal research approaches to this disorder. This knowledge gap has
constrained our ability to develop new and more effective phar-
macotherapies for schizophrenia (7), accounting for little change
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in the public health impact of this disease over the past two
decades (8).
Disturbances in the structural and functional connectivity of
the cerebral cortex are thought to be central to the neurobiol-
ogy of schizophrenia (6) and are thought to impair the function
of large-scale neural systems (9–13). Efforts have been made to
reconcile these system-level observations with the cellular neu-
ropathology of schizophrenia. One leading mechanistic model
proposes that glutamate synaptic abnormalities associated with
schizophrenia, mimicked in part by the effects of drugs that block
the N -methyl-d-aspartate glutamate receptor (NMDAR) (7), dis-
turb the local balance of excitation and inhibition and thereby
contribute to alterations in large-scale neural system functional
connectivity (14). This influential hypothesis is based on a key
observation: sub-anesthetic doses of non-competitive NMDAR
antagonists such as ketamine produce symptoms resembling those
of schizophrenia in healthy humans (15). There is also growing
evidence from pre-clinical (16), post-mortem (17), neuroimag-
ing (18), and pharmacological experiments (15) illustrating that
abnormal NMDA receptor function may be one pathophysiolog-
ical mechanism occurring in people with schizophrenia. Alter-
ations in synaptic function of gamma-aminobutyric acid (GABA)
(19, 20) and dopamine (21) have also been implicated in schizo-
phrenia, which likely affect local circuit computations (22). Collec-
tively, this work provides insight into how disturbances in synaptic
glutamate signaling (among other neurotransmitters) could con-
tribute to producing schizophrenia symptoms (7). Nevertheless,
there remains an important explanatory gap between mechanis-
tic cellular-level hypotheses of schizophrenia and non-invasive
neuroimaging studies that characterize the function of neural
systems.
Functional neuroimaging has consistently revealed both
region-specific and network alterations in schizophrenia across
a number of cognitive measures (23). For instance, there is now
substantial evidence suggesting profound alterations in networks
supporting complex cognition in schizophrenia [e.g., working
memory (WM) (24–26)]. This work has been complemented by
a parallel focus on characterizing functional connectivity alter-
ations in schizophrenia (27). Resting-state functional connectivity
is based on the analysis of low-frequency fluctuations present in
the blood-oxygenation-level-dependent (BOLD) signal (28, 29).
These low-frequency fluctuations have been shown to be tempo-
rally correlated within spatially distinct but functionally related
networks (30), establishing an intrinsic functional architecture
(31) across species (32). The functional networks identified at
rest also are correlated with other measures of structural and
functional connectivity in healthy populations (33) and allow
for characterization of distributed circuit abnormalities in neu-
ropsychiatric illness (34, 35). Such approaches have been success-
fully applied to the study of schizophrenia and have increasingly
revealed neuroimaging markers of this complex illness (12, 27, 36–
38), which may be consistent with established theoretical models
of this disease (39).
This review first focuses on resting-state functional connectiv-
ity MRI (rs-fcMRI) studies of schizophrenia that are providing
distinct insights into cortical dysfunction associated with this
disorder (37, 38). We highlight emerging connectivity strategies
that deal with the complexity and heterogeneity of schizophrenia
anatomy, physiology, and behavior (40). For instance, we articu-
late how data-driven tools that capture distributed connectivity
abnormalities – such as global brain connectivity (GBC) – have
the potential to avoid biases and identify network disturbances
that traditional seed-based approaches may fail to detect. We next
detail recent specific efforts to assay thalamo-cortical dysfunction
in schizophrenia (38), long thought to be important to the clini-
cal features of this disorder (41–43). We also discuss the potential
utility of such data-driven approaches to discover variations in
large-scale systems that may be altered across diagnostic categories
(e.g., bipolar illness with psychosis and schizophrenia) and that
may inform symptom-based or circuit-based diagnostic systems,
such as the NIMH Research Domain Criteria (RDoC) (44–46).
The encouraging progress in understanding functional con-
nectivity alterations in schizophrenia creates new opportunity to
reconcile system-level findings with hypotheses emerging from
molecular and cellular studies of this disorder. Failure to integrate
these multiple levels of research undermines our understand-
ing of the pathophysiology of this disorder and it will impede
medications development. To this end, we next turn to studies
using pharmacological models (47), such as the NMDAR antag-
onist ketamine, to test hypotheses related to the causes of circuit
dysfunction in schizophrenia (18). Here we review a focused set
of pharmacological neuroimaging (ph-fMRI) studies that uti-
lized NMDAR antagonists to alter behavior and connectivity in
healthy volunteers as a way to better understand schizophrenia
(18, 48–54). These ph-fMRI investigations provide insight into
how specific manipulations of synaptic function have effects that
scale to produce both behavioral and system-level alterations that
may be observed in patients. We articulate a set of directions for
future studies that can capitalize on ph-fMRI as a tool to provide
insight into specific illness-related mechanisms, especially when
combined with advanced functional connectivity approaches.
Finally, we briefly articulate the utility of neuroscience theory
and computational models for iteratively guiding our pharma-
cological and clinical experiments (55, 56). We focus on one
type of computational modeling that may hold promise in this
regard – namely, biophysically realistic computational models
that contain cellular-level detail necessary to characterize specific
synaptic disturbances that may occur in disease states (56, 57).
This level of biophysical detail can provide a vital opportunity to
test both hypothesized synaptic alterations in schizophrenia (55)
and also possible pharmacotherapies that may attenuate such dis-
turbances (58). Despite possible advantages, we note some key
limitations of these modeling approaches, pertaining to the con-
strained behavioral repertoire and neural architectures that are
currently effectively modeled in this way, largely owing to gaps
in our basic understanding of neurobiology that can constrain
such models. Therefore, we articulate a key objective for the future
of schizophrenia research: biophysically realistic computational
models need to be systematically developed and scaled to the
level of neural systems (59), to inform fMRI-level observations
in schizophrenia as well as those observed following pharmaco-
logical manipulations in healthy humans (Figure 1). We argue
that this approach could be especially productive for the study
of functional connectivity in psychiatric conditions, with the
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FIGURE 1 | Understanding complex mental illness from synapses to
circuits to neural systems. A major challenge facing the field of clinical
neuroscience is building the links across levels of inquiry, from the level of
receptors and cells, to microcircuits, and ultimately scale to the level of neural
systems and behavior. At present, there is a vast explanatory gap across
these levels in our understanding of psychiatric symptoms (top panel).
Bridging this gap represents a major effort in explaining how alterations of
specific mechanisms across neural systems may produce complex behavioral
alterations seen in serious mental illness. This challenge is also exemplified by
the National Institute of Mental Health Research Domain Criteria (RDoC)
initiative (45) in order to map the biology across levels of inquiry onto behavior
in a more systematic and data-driven way. We argue that computational
modeling approaches (55) combined with additional experimental tools such
as functional neuroimaging and pharmacology (47) offer one possible path
toward this objective (bottom panel). We detail emerging efforts in functional
connectivity work that may present a unique opportunity in this regard (59).
Note: top left receptor figure was adapted with permission from Kotermanski
and Johnson (60).
ultimate aim of developing mechanistically derived biomarker
predictions.
Building on these insights, we emphasize the need for efforts
to translate our basic discoveries in neuroscience and cellular-
level hypotheses in schizophrenia with system-level observations
that may directly relate to the complex behavioral abnormali-
ties observed in this illness. We highlight multiple complemen-
tary neuroscientific approaches, including recent clinical stud-
ies (37), pharmacological neuroimaging experiments (54), and
theoretical/computational neuroscience approaches (18, 58) that
can be synergistically harnessed to inform our understanding
of underlying mechanisms and guide development of better
pharmacotherapies for schizophrenia.
DEVELOPMENTS IN FUNCTIONAL CONNECTIVITY
APPLICATIONS TO NEUROPSYCHIATRIC DISEASE
Nearly two decades ago Biswal and colleagues (61) demonstrated
that coherent fluctuations in the BOLD signal exist across time
and space, demarcating a functional network architecture in the
human brain. Such early studies highlighted this phenomenon by
focusing on the fluctuations between the left and right motor cor-
tex. This key property of the BOLD signal has in turn generated a
paradigm shift in non-invasive human neuroimaging and allowed
for characterization of distributed neural networks across species
in the absence of task-mediated effects (28–30, 32, 62). Impor-
tantly, a close correspondence between resting-state networks and
task-based networks has been established within individual sub-
jects and using meta-analytic techniques (31). The value of this
approach has been enhanced by the subsequent emergence of ana-
lytic techniques that have provided insights into the component
structure and regulation of distributed cortical networks (62). For
instance, recent advances in graph-theoretical approaches have
shown that cortical and subcortical networks can be segregated
into unique community structures, providing a comprehensive
data-driven mapping of human functional networks (63). Another
set of studies has demonstrated the temporal non-stationary prop-
erties of the large-scale functional networks, delineating temporal
functional modes of the human brain (64). In other words, there
seem to be distinct and independent patterns of connectivity
over both space and time. Although a comprehensive review of
connectivity method developments is beyond the scope of this
manuscript, we refer the reader to recent detailed reports on this
topic (62). Here we specifically focus on select clinical applications
in schizophrenia and bipolar illness.
Resting-state functional connectivity MRI approaches have
been increasingly applied to neuropsychiatric illness (65). Use of
this technique is built upon the hypothesis that specific neuropsy-
chiatric conditions are brain disorders that affect computations
across large-scale networks of regions or specific circuits in such
a way that these alterations can be identified with functional
connectivity measures. This hypothesis suggests that such distur-
bances in neural network function may reflect alterations in more
basic cellular-level mechanisms. Thus, disturbances in molecu-
lar signaling or synaptic function would be hypothesized to scale
and produce disturbances in large-scale neural systems (66). Such
network-level disturbances in a given functional system may then
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reflect specific psychiatric symptoms (12, 27). This framework has
guided the application of functional connectivity with the objec-
tive of identifying putative biomarkers via BOLD fMRI that could
reveal neural system-level disturbances in neuropsychiatric condi-
tions even in the absence of specific tasks. Such an approach may
hold promise if its sensitivity and specificity is ultimately refined
to the point of diagnostic utility.
Specific advantages of rs-fcMRI include: (i) speed, as the func-
tional network architecture can be reliably assayed within 10 min
of data acquisition (67), and perhaps even faster with recent
advances in multi-band imaging technology (68, 69); (ii) possi-
ble cost-effectiveness. Task-based studies may require longer time
for data acquisition, depending on the precise paradigm being
imaged. (iii) Lack of performance confounds, which likely affects
nearly every cognitive activation task when applied to a psychiatric
population (70). (iv) In addition, when coupled with techniques
such as GBC or independent component analyses (ICA), rs-fcMRI
studies allow the unbiased, simultaneous examination of all neural
networks (see below for more discussion). All of these features sug-
gest that rs-fcMRI may be a feasible method for eventually guiding
and tracking symptoms, illness progression and possibly response
to pharmacotherapies and/or behavioral treatments.
The approach itself, however, is not without limitations. For
instance, the size of the correlation coefficient is often used to
examine the strength of coupling between different network nodes
(71). While this is an analysis-level consideration, the major-
ity of published studies use this technique. This approach may
not be ideal for examining shared versus non-shared variance
between regions and may obscure more complex differences that
could occur in psychiatric conditions (71). For instance, it may
be important to uniquely identify functional connectivity alter-
ations that truly reflect altered neuronal communication between
two network nodes, as opposed to the influence of a third region
on both (a correlation-based approach could not disambiguate
these possibilities). It is also important to emphasize that func-
tional connectivity, as measured at rest, is purely correlational and
therefore can only be used to make tentative causal inferences.
That is, if there is evidence for an alteration in a given circuit,
this alteration could be predictive of disease onset or could be
a consequence of some upstream physiological alteration. More-
over, there are additional complications involved in the study of
neuropsychiatric illness concerning what is a primary deficit, as
opposed to a compensation or treatment effects. These potential
confounds underscore the complementary value of causal exper-
imental designs involving pharmacologic, neuro-stimulation, or
cognitive manipulations of circuit activity. Finally, there are still
notable differences in the methods used to analyze rs-fcMRI data.
For instance, one ongoing controversial issue relates to removal of
the global signal (i.e., global signal regression, GSR) from func-
tional connectivity data (72, 73). This step effectively regresses out
variance associated with global brain fluctuations, which can be
large in magnitude and can perhaps obscure certain real func-
tional relationships (74). Nonetheless, this step effectively shifts
the mean of the connectivity distribution, resulting in a portion
of correlations being moved into the negative range – thus spuri-
ously inducing at least some anti-correlations. There is convincing
evidence from electrophysiology experiments using animals that
anti-correlations indeed exist (75, 76). However, GSR could still
complicate some aspects of between-group comparisons and the
interpretations of clinical studies (73), especially when examining
system-level relationships across groups. Therefore, future studies
should carefully continue to consider the possible impact of this
step on between-group differences in clinical rs-fcMRI studies.
Another methodological issue pertains to how networks are
identified. Many early functional connectivity studies both in
healthy adults and in clinical populations used a seed-based
approach, whereby the correlation from a given region of inter-
est is examined with all other voxels in the brain. This approach
has also been complemented by more complex graph theoretical
and network-based methods (77). Seed-based approaches inher-
ently assume a consistent difference across a set of regions in a
clinical condition. However, the pattern of dysconnectivity for a
single region could indeed be more variable both across subjects
and within regions. Such spatial variability in functional networks
across subjects may present a limitation of seed-based approaches
when applied in studies of clinical populations (11, 40). This may
be the case in complex mental illnesses such as schizophrenia.
Therefore, detecting more complex patterns of dysconnectivity
requires new approaches taking into account these confounds
(78–80).
New methods are needed to detect more complex patterns of
disorder-related disturbances in connectivity (80), illustrated by
the GBC approach (11, 35, 40, 81). The GBC technique is specifi-
cally designed to consider connectivity from a given voxel or (area)
to all other voxels (or areas) simultaneously by computing either
average connectivity strength (weighted GBC) or by counting the
number of connections above a given connection strength (un-
weighted GBC). Thus, this approach is data-driven and unbiased
as to the location of connectivity disruption. That is, unlike typ-
ical seed-based approaches, GBC requires only the seed region
to be relatively consistently located across subjects, while the tar-
get regions can vary substantially across subjects (Figure 2). For
example, if a given area is perturbed in its functional connectivity
consistently, irrespective of the overall network spatial configura-
tion where the perturbation is, GBC will remain sensitive to this
alteration. Further, unlike typical seed-based approaches, GBC
involves one statistical test per voxel (or ROI) rather than one
test per voxel-to-voxel pairing – substantially reducing multiple
comparisons (e.g., 30,000 rather than ~900 million tests). These
two improvements over typical seed-based approaches can dra-
matically increase the chance of identifying group differences in
connectivity, or individual differences in connectivity correlated
with behavioral symptoms (11, 35, 40, 81). Indeed, consistent with
these proposed advantages, GBC has now been applied to identify-
ing regions with large-scale disruptions in functional connectivity
across a variety of mental illnesses, such as schizophrenia (11),
bipolar disorder (35), and obsessive-compulsive disorder (OCD)
(82). GBC is explicitly designed to address questions about brain
connectivity that are qualitatively distinct from traditional seed-
based functional connectivity analyses. For instance, areas of high
GBC are “hubs” of connectivity in the brain that are maximally
functionally connected with other areas and may play a role in
coordinating large-scale patterns of brain activity (40). In that
sense, a group difference in GBC may reflect areas and networks
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Subject 1 Subject N Group
GBC
Group
seed/ICA
... =
Consistently high mean
dysconnectivity
Inconsistent
dysconnectivity pattern
B
Group
GBC
Group
seed/ICA
Subject 1 Subject N
... =
C
Consistently high mean
dysconnectivity
Consistent
dysconnectivity pattern
A Voxel 1 Voxel N Within-subject
GBC
Within-subject
seed/ICA
... =
Consistently high mean
dysconnectivity
Inconsistent
dysconnectivity pattern
Dysconnection of region to voxel(s)
No dysconnection of region to voxel(s)
Signi cant dysconnection of voxel to other regions
FIGURE 2 | Global brain connectivity identifies globally dysconnected
regions despite substantial within or between subject variability. We
hypothesized that some brain regions may have global variable disruptions in
functional connectivity, which may contribute to individual differences in
symptom severity in brain disorders. GBC can be used as a data-driven
approach to search for such regions. GBC is computed as the average
connectivity of each voxel to all others. Gray circles indicate regions with
altered connectivity to the depicted red voxels. (A) GBC will identify a region
with consistent global dysconnectivity even when there are substantial
differences in connectivity patterns within the region. Seed or ICA approaches
would be unable to identify dysconnectivity in such a region because of
inconsistent dysconnectivity patterns across neighboring voxels. (B) GBC,
unlike seed or ICA approaches, will identify a region with consistent global
dysconnectivity even when there are substantial individual differences in
connectivity across subjects. This allows the identification of regions with
many individual differences in connectivity, which might correlate with
individual differences in symptoms. (C) GBC is also sensitive to consistent
group differences in connectivity that might be identified using seed or ICA
approaches, though GBC might be more sensitive due to pooling of results
for both consistent and inconsistent dysconnectivity. GBC, global brain
connectivity; ICA, independent component analysis. Note: figure adapted
with permission from Cole and colleagues (11).
in which the large-scale coordination of information process-
ing is affected in the disease state. For instance, decreased GBC
may reflect decreased participation of a brain region in broader
networks. Conversely, increased GBC may suggest a pathological
broadening or synchronization of functional networks. Related
to this point, we have now published a manuscript examining
distributed networks in OCD using GBC where specific striatal
and orbitofrontal circuits have been implicated. Yet, GBC remains
sensitive to alterations in neuropsychiatric conditions that may
actually be associated with more focal deficits (which may be the
case in OCD versus schizophrenia). In that sense, GBC is not
necessarily more useful for “global” versus “restricted” deficits,
but rather dysconnectivity to a given “hub” region that may be
affected in its participation in wide-spread neural networks. These
properties of GBC – detection of regions with large-scale func-
tional connectivity disruptions along with tolerance for individual
differences – makes this method particularly powerful for identify-
ing regions with consistently large and distributed disruptions that
have functional consequences reflected in individual differences in
psychiatric symptoms. Continued refinement of graph-theoretical
data-driven metrics such as GBC may allow a powerful path for-
ward for delineating biomarkers within and across diagnostic
categories.
Another data-driven method that has increasing applications
in psychiatric neuroimaging involves ICA of BOLD signal fluctua-
tions at rest. Here ICA provides a tool to identify spatially (78,
83) or temporally (64) independent modes of brain function.
ICA has been successfully used to identify distributed network
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abnormalities in both schizophrenia and bipolar illness (84). In
particular, temporal ICA (64) may provide a novel and power-
ful method to assay the non-stationary properties of distributed
neural systems across different clinical conditions. It remains to be
systematically tested if recently defined temporal functional modes
exhibit alterations in neuropsychiatric illness. One possibility,
given wide-spread neurotransmitter disruptions in schizophrenia,
is that the temporal functional modes are substantially more non-
stationary in this illness. Powerful new acquisition sequences [e.g.,
multi-band imaging (68)], that allow much finer temporal sam-
pling, will provide critical technological innovations at the level
of neuroimaging acquisition with direct clinical applications, in
particular when using ICA-type measures.
Collectively, the continued success of these methods suggests
that ongoing refinement of tools to examine functional connec-
tivity remains vital for development of biomarkers for psychiatric
illness. Next, we turn to specific findings in the field of schizophre-
nia and bipolar research. We detail recent methodological advances
in connectivity work that have been directly applied to better
understand network disruption in these psychiatric conditions.
EMERGING EVIDENCE SUGGESTS LARGE-SCALE
DYSCONNECTIVITY IN SCHIZOPHRENIA
There are now a number of influential hypotheses suggesting
that, at its core, schizophrenia may be a disorder of large-scale
neural connectivity (6, 85), i.e., “dysconnectivity.” Here we refer
to dysconnectivity as an alteration in neural communication that
specifically produces behavioral pathology, as opposed to a simple
alteration in functional connectivity that deviates from the norm.
The models proposing such dysconnectivity range from theoreti-
cal to formal computational hypotheses (42, 43, 66, 86–88). This
work has inspired the search for connectivity biomarkers for schiz-
ophrenia and it broadly includes: (i) studies that use rs-fcMRI, that
is investigations that study the intrinsic properties of BOLD sig-
nal fluctuations to delineate system-level alterations in psychiatric
illness (27); (ii) studies that examine task-based dysconnectivity,
that is alterations in connectivity during specific task contexts;
(iii) pharmacological studies of individuals at rest or perform-
ing tasks, which we discuss in the upcoming section. While the
literature on task-based connectivity has offered important clues
regarding network alterations during specific cognitive processes
(e.g., WM) (27, 89, 90), here we specifically detail emerging efforts
to use rs-fcMRI to define biomarkers for schizophrenia. This
is not to say that characterizing functional connectivity during
cognitive processing is not important. In fact, such studies repre-
sent a vital effort to move our understanding beyond activation-
based hypotheses regarding cognitive deficits in schizophrenia or
regional hypotheses of specific symptoms. In the future, task-based
functional connectivity studies will ultimately aid our understand-
ing of network dysfunction with respect to specific symptoms or
specific cognitive processes known to be profoundly affected in
schizophrenia (e.g., WM) (26). Additionally, task-based studies
of functional connectivity provide an important assurance that
observed differences in resting-state functional connectivity do not
merely reflect differences in the dynamics and content of mental
processes subjects might engage in during rest, but rather stable
disruptions in functional connectivity that persist across mental
states (90). However, rs-fcMRI can be used to identify neural-
system alterations even more broadly. With that in mind, we argue
that rs-fcMRI offers a unique tool to identify distributed neural
system alterations, extending beyond a given task context. More-
over, as noted above, this approach in particular bypasses task
performance confounds which plague the task-based activation
literature (70) and such concerns will likely extend to task-based
connectivity work.
Despite its promise, a major obstacle in delineating successful
neural markers for schizophrenia (or any other severe neuropsy-
chiatric disease) using connectivity (or any other approach for
that matter) has been the complexity of this illness and the vast
range of behaviors it affects (91), as well as the complex temporal
dynamics of its progression. That is, the apparent clinical complex-
ity of schizophrenia is a major obstacle to biomarker development
that may apply to all patients. In addition, the associated clinical
heterogeneity (i.e., differences in symptoms across patients), the
presence of numerous comorbidities and environmental modi-
fiers, the ubiquitous confound of long-term antipsychotic treat-
ment, and the wide range of affected behaviors collectively reduce
the likelihood that a single biomarker would be applicable to the
entire syndrome. Moreover, many researchers and clinicians would
argue that schizophrenia is a theoretical construct used to label
co-occurring symptoms whereby it may be challenging (or per-
haps impossible) to map out a reliable and replicable marker of
the entire syndrome in a parsimonious way [although theoret-
ical models of the disease often consider it as one entity (66)].
We argue that functional connectivity tools offer a useful path for-
ward in this regard by providing methods to test specific large-scale
dysconnectivity patterns in relation to this heterogeneity that may
be otherwise difficult to capture.
Certain studies using rs-fcMRI have, however, attempted to
deal with clinical heterogeneity by focusing on the relationship
between altered functional connectivity in specific pathways and
linking those pathways to particular features of schizophrenia.
For instance, studies by Hoffmann and colleagues have focused
on better understanding alterations in connectivity specifically
associated with auditory hallucinations (92), which many patients
experience (1). They found compelling evidence for disruptions
between regions associated with auditory processing. Specifically,
they found that when they seeded Wernicke’s area, there was signif-
icantly greater functional connectivity to Brodmann’s areas 45/46
among hallucinating patients compared with non-hallucinating
patients. In a subsequent analysis, they reported that the functional
connectivity within a functional loop including the Wernicke’s
area, inferior frontal gyrus, and putamen was robustly greater for
hallucinating patients compared with non-hallucinating patients.
Vercammen and colleagues also found that patients with schiz-
ophrenia evidenced attenuated functional connectivity between
the left TPJ (temporo-parietal junction) and the right Broca’s area
(93). These are examples where targeted seed-based approaches
may identify alterations in circumscribed circuits associated with
specific symptoms.
Another set of emerging studies have studied the “salience” and
“control” systems, focused on striatal and insular dysconnectivity
in schizophrenia (94, 95), particularly in relation to the “aber-
rant salience” hypothesis (96, 97). Briefly, the “aberrant salience”
Frontiers in Psychiatry | Schizophrenia December 2013 | Volume 4 | Article 169 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anticevic et al. Connectivity, pharmacology, and computation in schizophrenia
hypothesis has been linked to abnormal striatal dopamine func-
tion, suggesting that during psychotic states patients have a higher
likelihood of forming inappropriate associations and respond
excessively to random neutral events. Related to this issue a study
by Tu and colleagues examined whether schizophrenia is associ-
ated with functional connectivity alterations within the cingulo-
opercular (CO) network specifically (98). They identified signif-
icantly reduced functional connectivity in the bilateral putamen
for patients with schizophrenia, which was related to cognitive
performance in patients. The authors concluded that schizo-
phrenia is associated with disconnection within cortico-striatal
circuits. A complementary study by Moran and colleagues (99)
focused on the anterior insula as a key node involved in modu-
lation of distributed neural systems (as part of the CO system).
The authors tested for disruptions in the functional relationships
between the insula and control/default networks in patients with
schizophrenia. Similarly, they examined a relationship between
these network disturbances and cognitive deficits. Consistent with
a priori predictions, Moran and colleagues found strong sup-
port for the disrupted relationship between the anterior insula
and the control-executive and default-mode networks in schiz-
ophrenia, which again was predictive of cognitive performance.
Most recently, a study by Palaniyappan and colleagues (100) also
focused on the relationship between the salience (insular) sys-
tem and the executive [lateral prefrontal cortex (PFC)] networks
in schizophrenia. They explicitly tested for evidence of disrupted
directional influence across the networks. In other words, similar
to Moran and colleagues, they used an auto-regressive technique
(i.e., Granger causality) to examine both feed-forward and rec-
iprocal connectivity between the aforementioned networks. The
authors reported significant differences in patients with regard
to time-lagged functional relationships between executive and
insular systems. The authors conclude that this “breakdown” in
directional functional relationships may reflect aberrant process-
ing of novel salient information. These studies provide compelling
emerging evidence that there may indeed exist causal breakdowns
across functional networks in schizophrenia. Nevertheless, it is
important to note that lag-based causality measures in the con-
text of BOLD signal analyses have not been without controversy
(101–103), primarily because of systematic difference in the hemo-
dynamic response function lags across areas. Given these concerns,
the use of Granger causality in rs-fcMRI studies needs to be inter-
preted with caution [see Ref. (104) for a more detailed treatment
of using auto-regression techniques with the BOLD signal]. Future
studies using concurrent electrophysiology/fMRI protocols could
provide convergent evidence to address issues regarding temporal
dependencies across cortical networks when analyzing the BOLD
signal.
We discussed studies that focused on either specific regions
or networks that may be abnormal in schizophrenia. An alter-
native tactic, precisely because of the complexity of this illness,
is to use data-driven methods to study large-scale connectivity
alterations that may be difficult to pinpoint a priori. A num-
ber of prominent and well-established models of schizophrenia
neuropathology implicate profound disruptions in PFC function
(105), likely stemming from a confluence of glutamate, GABA, and
dopamine alterations that could jointly affect PFC function (7, 19,
106–108) (see Box 1). One area that has been repeatedly implicated
in schizophrenia neuropathology is the dorso-lateral PFC (23).
However, this evidence has largely been marshaled through task-
based studies such as those examining WM deficits in this illness
(70). A deficit in task-evoked computations of a given region does
not necessarily guarantee that the same node will show other forms
of functional “dysconnectivity.” Moreover, such evidence does not
guarantee that this same area may be disrupted in its functional
connectivity in the absence of a task (i.e., during resting-state).
Nevertheless, PFC functional deficits have been considered a hall-
mark feature of the illness. Therefore, one promising approach is
to examine global PFC dysconnectivity in a data-driven way.
As articulated above, the GBC functional connectivity approach
is specifically designed to test the hypothesis that a given func-
tional brain region has altered coupling with the rest of the brain
(or a large anatomical portion of the brain, such as the PFC). To
test the efficacy of this approach, Cole and colleagues (11) used
a restricted GBC (rGBC) approach focused on PFC in particu-
lar in a sample of patients with chronic schizophrenia relative
to demographically matched healthy comparison subjects. Cole
and colleagues reported that bilateral regions centered on the lat-
eral PFC showed reductions in their PFC rGBC, suggesting that
these regions have profound alterations in their connectivity pat-
terns with the rest of PFC. To further test the relationship between
identified PFC rGBC alterations and cognitive deficits, Cole and
colleagues quantified the relationship between IQ and the PFC
global connectivity alterations. The authors found that greater
connectivity between the identified lateral PFC and the rest of PFC
predicted better cognitive performance, suggesting that a lower
index of global PFC coupling may in part relate to cognitive deficits
in schizophrenia. Moreover, the authors additionally examined
the pattern of whole-brain coupling of the discovered right lat-
eral PFC region using seed-based techniques. The authors found
that patients diagnosed with schizophrenia showed increased cou-
pling with sensory cortices (Figure 3B, posterior regions, shown
in yellow-red). Patients also showed reduced connectivity with
prefrontal and other higher-order temporal regions (Figure 3B,
shown in blue). Collectively, this initial report demonstrates that
data-driven functional connectivity approaches could identify
regions previously implicated in schizophrenia using task-based
methods. Moreover, these identified areas showed robust and com-
plex alterations of connectivity with the rest of the brain and
importantly, related to observed symptoms and other cognitive
measures.
Similar data-driven efforts have been applied to study global
connectivity alterations in other psychiatric conditions. Specif-
ically, Anticevic and colleagues extended the approach to study
bipolar patients with and without a history of psychotic symp-
toms (35). While examining neural system-level disturbances in
schizophrenia is a vital objective, psychosis occurs across a number
of diagnostic categories. For instance, many bipolar patients expe-
rience frank psychosis (121). Given this clinical observation, some
studies divide bipolar patients based on the presence or absence
of psychotic symptoms (122, 123). In that sense, there may be
somewhat limited utility in predefined diagnostic boundaries for
understanding variation in neural circuits that could possibly be
affected across neuropsychiatric conditions (45). Recognizing this
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Box 1 Glutamate versus dopamine: upstream versus down-stream mechanisms in schizophrenia.
It is increasingly acknowledged that schizophrenia is associated with disturbances in multiple neurotransmitter systems, including alterations
at the cortical microcircuit level in glutamate and γ-aminobutyric acid (GABA), as well as disturbances in dopaminergic neurotransmission
along striatal-thalamic-cortical pathways (7, 106, 109). Additional studies have also implicated the glial system as possibly compromised
in schizophrenia (110, 111) and other neuropsychiatric conditions (112). However, it remains unknown whether dopamine or glutamate
alterations are the upstream causes or down-stream consequences of the disease process (109). Addressing this question has important
implications for appropriately constraining computational models, both at the microcircuit level (58) and expanding those mechanisms to the
system-level (18).There are two broad possibilities to consider: (i) there may be dissociable groups of patients each associated with a primary
abnormality in one of the broad neurotransmitter systems, but as a consequence there may be secondary abnormalities in the other system
due to shared pathways and functional loops (43, 88). (ii) One alternative possibility is that there are always primary alterations in only one
of the two systems, followed by alterations in the other. Disambiguating between these causal possibilities can have important implications
for developing optimized targeted pharmacotherapies for specific patient groups, which is a likely possibility given the heterogeneity of
the illness. By extension, resolving these issues may have implications for optimized pharmacotherapies for a given phase of illness [if
initial stages of schizophrenia are primary associated with hyper-glutamatergic neurotransmission (113)]. Also, these two possibilities have
important implications for the utility of pharmacological models of psychosis (e.g., amphetamine versus the NMDAR antagonist challenge
studies in healthy volunteers).
Here it is important to consider some key differences between the dopamine and glutamate hypotheses in schizophrenia in relation to phar-
macological findings and their therapeutic effects: (i) dopaminergic medication has not proved successful at ameliorating the full range of
impairing symptoms in schizophrenia, particularly cognitive deficits (26); (ii) pharmacological models of schizophrenia targeting the dopamine
system (e.g., amphetamine challenge) have typically produced a clinical profile marked by acute psychosis, as opposed to a broader range
of symptoms produced by pharmacological agents targeting the glutamate system (15, 114, 115). Therefore, while it is certainly important
to acknowledge dopamine as a key component of disrupted neurotransmission in schizophrenia (21, 116, 117), it remains to be determined
if dopamine is indeed a down-stream cause or a consequence of primary disruptions in glutamate (118). Relatedly, irrespective of cause or
consequence arguments it will vital to consider the diversity of DA receptors (D1 versus D2) and their respective sites of influence in cortex
(22, 119, 120) versus striatum (108), which in turn generates important constraints for computational modeling studies that incorporate
dopaminergic and glutamatergic signaling mechanisms.
FIGURE 3 | Neural system-level dysconnectivity in
schizophrenia – emerging biomarkers. (A) Results from a recent large
connectivity investigation examining thalamo-cortical connectivity alterations
in 90 patients diagnosed with schizophrenia relative to 90 matched healthy
controls (38). Anticevic and colleagues found robust alterations in
thalamo-cortical information flow in schizophrenia, whereby sensory-motor
cortical regions showed over-connectivity in schizophrenia (regions shown in
yellow-red), but prefrontal-striatal-cerebellar regions showed under
connectivity in schizophrenia relative to controls (regions shown in blue).
Anticevic and colleagues fully replicated this pattern in an independent
sample. Woodward and colleagues, using complementary approaches, found
highly comparable effects (37). (B) A similar pattern of over/under connectivity
was identified in patients with schizophrenia when using a DLPFC seed
region identified via GBC; as with the thalamic seed, there was increased
coupling with sensory (posterior regions, shown in yellow-red) but reduced
connectivity with prefrontal and other higher-order temporal regions (shown
in blue). This over/under pattern recapitulated qualitatively the observations
found for the thalamic analysis in (A), as shown in the distribution plots on the
bottom of each panel. Note: figures adapted with permission from Anticevic
and colleagues (38) and Cole and colleagues (11).
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limitation, there are emerging efforts to map common aspects of
neural dysfunction across diagnostic categories.
Focusing on bipolar illness, Anticevic and colleagues exam-
ined the possibility that there are similar abnormalities in bipolar
illness with a history of psychosis to those found in schizophre-
nia. Consistent with this hypothesis, Anticevic and colleagues
found that bipolar illness is indeed associated with altered PFC
rGBC specifically in a medial prefrontal/ventral cingulate region
implicated in regulation of emotion (35). Importantly, this effect
was primarily driven by a presence of psychosis history, and the
magnitude of the observed PFC rGBC disruption was correlated
with the severity of prior psychosis. This effect, however, was
obtained in euthymic bipolar individuals (as opposed to symp-
tomatic schizophrenia patients above), which suggests that at least
some alterations in global connectivity may be a stable (trait) fea-
ture of the illness and may not necessarily only manifest in overtly
symptomatic individuals. In that sense, data-driven functional
connectivity may provide a tool to examine individual variabil-
ity in both current and/or lifetime symptoms. Such data-driven
approaches can also be used to establish alterations in functional
neural architecture over time – namely, whether the observed dis-
ruptions in schizophrenia and bipolar illness change longitudinally
as the illness progresses. This possibility is consistent with promi-
nent neurodevelopmental models of severe psychiatric illness (14,
124–126), which suggest that there may be profound functional
changes along the illness progression, to which these tools may be
sensitive.
While promising, a key challenge facing data-driven approaches
will be to establish whether identified effects consistently replicate
across sites and samples. It may be possible that illness sample
heterogeneity, illness stage, symptom severity, anatomical het-
erogeneity, or other factors will critically impact the patterns of
data-driven effects across studies and samples. That is, it may be
possible that different foci are detected as showing disruptions in
different samples. Therefore, it will be critical to determine which
of the identified data-driven global connectivity alterations are
stable and replicable (perhaps capturing some core disturbances)
and which alter as a function of other variables (perhaps captur-
ing state effects). Such ongoing data-driven efforts should also
continue to capitalize on recent advances in graph theory (80)
as well as neuroimaging acquisition-level improvements (64, 69,
127) which could jointly improve the sensitivity of resting-state
connectivity-derived metrics.
As described above, the PFC has been repeatedly implicated
in schizophrenia neuropathology. However, despite data-driven
efforts to map PFC dysfunction, the PFC remains a challenge in
the study of schizophrenia, owing largely to the complex individual
differences in function and anatomy of the PFC. Therefore, to ulti-
mately establish a viable large-scale, brain-wide marker of neural
alterations in schizophrenia, an alternative approach can be taken.
One possible path is to start from the thalamus as a key region
of interest (42). That is, while the PFC has classically been impli-
cated in schizophrenia neuropathology, recent studies highlight
disturbances in additional neural foci. In particular, the thalamus
has emerged as an important disrupted locus in schizophrenia.
While we presented some arguments against using seed-based
approaches, the thalamus may present a unique opportunity in
this case. Here we argue for the utility of specifying a seed when
there is a specific theoretically guided hypothesis implicating a
given area in the disease process. In this case, examining thala-
mic connectivity using rs-fcMRI in schizophrenia capitalizes on
several key aspects of this subcortical region: (i) the thalamus is
topographically connected to the entire cortex (128, 129), and may
therefore represent a node particularly sensitive to network-level
disturbances (42); and (ii) the thalamus contains anatomically and
functionally segregated nuclei readily identifiable via neuroimag-
ing (130) thus providing a lens for examining parallel yet dis-
tributed large-scale connectivity disturbances in neuropsychiatric
disease.
Consistent with this view, a large body of evidence impli-
cates significant thalamo-cortical communication disturbances in
schizophrenia neuropathology (41, 42, 131–134). In fact, a funda-
mental aspect of large-scale brain organization preserved across
mammalian species is thalamo-cortico-striatal sub-circuits that
are thought to integrate various functions such as emotion pro-
cessing and motor output (135–138). Such circuits may become
profoundly dysregulated in schizophrenia, and the thalamus, as
an organized hub of cortical and subcortical connections, may be
especially sensitive to such dysregulation. Essentially, the thala-
mus serves as a nexus for parallel circuits through which diverse
cortical and subcortical functions are integrated and distributed
throughout the cortical mantle (128, 139, 140). These thalamic
circuits have been implicated in schizophrenia pathophysiology
on the basis of neuropathology studies (88, 141–143), pre-clinical
lesion models (144, 145), structural imaging studies (146, 147),
and computational models (43). Moreover, thalamic abnormal-
ities are repeatedly implicated in sensory gating (148, 149) and
filtering disruptions (150, 151) associated with this disorder (42).
Indeed, one prominent model of schizophrenia neuropathology
is centered on the thalamus as a key hub of disrupted com-
putations in this illness. This “cognitive dysmetria” hypothesis
articulates a distributed disruption in information processing
across widespread cortical and subcortical nodes (39). In their
seminal theoretical piece, Andreasen and colleagues argue that in
order to explain the full range of schizophrenia symptoms, the
field has to move away from region-specific models, but rather
consider a distributed processing deficit, which could also parsi-
moniously explain a computational abnormality in a given node
of a distributed complex system. In that sense, the thalamus is a
uniquely positioned set of nuclei that communicates with virtually
every cortical territory and is likely to be profoundly affected in
schizophrenia.
Building on theoretical, pre-clinical, and anatomical work,
recent studies of functional connectivity have begun to map
thalamo-cortical alterations in schizophrenia. The first study to
do so, by Welsh and colleagues (152), focused on the medio-dorsal
nucleus of the thalamus as a seed region. This focused approach is
justified given that specific thalamic nuclei in schizophrenia may
show particularly profound functional connectivity disruptions.
The medio-dorsal nucleus projects heavily to PFC regions (153,
154), and is thought to be compromised in schizophrenia (142,
144, 155). Welsh and colleagues found lower connectivity between
the medio-dorsal nucleus and the PFC in patients with schizophre-
nia relative to healthy comparison subjects. However, this early
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investigation was based on a very small sample and could there-
fore be limited in its ability to provide conclusions regarding more
subtle disruptions elsewhere. Moreover, Welsh and colleagues
could not provide information regarding additional thalamic
nuclei given the explicit focus on the medio-dorsal nucleus. In a
subsequent study, Woodward and colleagues employed a substan-
tially more powered sample (N = 62) and extended the approach
to other thalamic nuclei (37). The authors used a parcellation
scheme of thalamo-cortical connections at rest provided by Zhang
and colleagues (129). In the study by Zhang and colleagues, corti-
cal areas were clustered into subdivisions that exhibited unique
functional connectivity with distinct thalamic nuclei based on
the similarities in resting-state BOLD signal. Woodward and col-
leagues harnessed this segmentation scheme to test the hypothesis
that unique thalamo-cortical circuits may show different patterns
of disturbances in schizophrenia. Strikingly, Woodward and col-
leagues found that compared to healthy controls, the thalamic
segmentations associated with the PFC showed reduced connec-
tivity in schizophrenia. In contrast, cortical territories centered on
sensory-motor regions showed increases in thalamic coupling in
schizophrenia. This evidence suggests that there exists a profound
alteration in thalamo-cortical information flow in schizophrenia
but one that seems to follow an anatomical dissociation between
sensory and higher order association regions. Building on this
robust evidence for thalamo-cortical alterations in schizophrenia it
is important to provide information about the specific connections
being affected. Specifically, the cortical parcellation scheme, while
a powerful initial demonstration, did not allow for examination
of the cerebellum for instance. Cerebellum is a structure that, like
the striatum, has projections to the cortex by way of the thalamus
(156), and has been implicated in schizophrenia pathophysiology
(39). Lastly, perhaps due to restricted power, the authors could not
examine subtle relationships between symptoms and identified
dysconnectivity.
A subsequent report by Anticevic and colleagues examined
thalamo-cortical dysconnectivity in 90 patients diagnosed with
schizophrenia relative to 90 matched healthy comparison sub-
jects (38). The key objective of this investigation was to determine
if thalamo-cortical disturbances span across diagnostic bound-
aries that share similar symptoms. This cross-diagnostic extension
directly informs the objectives articulated by the NIMH RDoC
initiative, which aims to develop biomarker-driven diagnostic
systems (45). First, the authors replicated the core findings by
Woodward and colleagues, demonstrating that schizophrenia is
associated with increased coupling between the thalamus and
all sensory-motor cortices. In contrast, frontal-striatal-cerebellar
nodes showed reduced coupling with the thalamus in schizophre-
nia relative to healthy comparison subjects (Figure 3A). Both
patterns were fully replicated in an independent and smaller sam-
ple of patients. Critically, further analyses demonstrated that these
two sources of disturbance were functionally related. That is,
those patients with the highest sensory-motor-thalamic coupling
also showed the lowest prefrontal-striatal-cerebellar-thalamic cou-
pling. This effect was most prominent for thalamic clusters cen-
tered on the medio-dorsal nucleus with known dense projections
to the PFC, ruling out the possibility of pan-thalamic dyscon-
nectivity that is uniform. Furthermore, the magnitude of the
sensory-motor-thalamic over-connectivity was correlated with
PANSS symptom severity across patients, confirming its functional
relevance. The magnitude of this correlation, however, was small
(r = 0.23) – indicating that the observed pattern explains only a
small portion of the variance in symptom variation across subjects.
An alternative possibility, given that the majority of patients were
quite symptomatic, is that the small magnitude reflects a restricted
range in symptoms whereby there was little variability in symptom
severity across the patient sample.
The identified thalamic dysconnectivity was successfully used
for diagnostic classification via multivariate pattern analysis
(MVPA) (157) with high levels of sensitivity and specificity across
both the discovery and replication samples. This implies that the
identified dysconnectivity patterns, while not yet qualifying for a
robust biomarker, may be refined and used to predict risk and
assess treatment response. In particular, there are major ongoing
improvements in neuroimaging acquisition (127) and processing
(69) technology as a direct consequence of the Human Connec-
tome Project (158) that can enable future studies to iteratively
refine neuroimaging approaches. Such studies can focus on the
identified patterns to ultimately improve methods and fine-tune
the identified patterns for biomarker use.
Lastly, the authors found that the bipolar illness sample exhib-
ited an“intermediate”pattern of disturbance such that the patterns
of thalamo-cortical connectivity were “shifted” relative to healthy
comparison subjects but not as severely altered as those identi-
fied in schizophrenia. This finding in particular offers promise
for using neuroimaging markers to inform our understanding
of shared disturbances in the underlying biology that cut across
diagnostic categories (123). The next step will be to understand
how such shared neural system-level “endophenotypes” (159, 160)
map onto co-occurring behavioral disturbances (e.g., psychosis)
as well as onto possibly shared alterations at the level of cortical
microcircuits (which we discuss in the last section).
Most recently, Klingner and colleagues provided convergent
results from a sample of 22 patients diagnosed with schizo-
phrenia and 22 matched comparison subjects (161). In their
study they separately examined the left and right thalamic seeds.
They found robust evidence for increased thalamic connectivity
with bilateral sensory-motor and auditory cortices. The authors
conclude that their results suggest a possible “lack of thalamic
control on motor/sensory information processing resulting in
increased (and less filtered) forwarding of information to the
prefrontal cortex.” This hypothesis is consistent with findings
from the two earlier and larger studies (37, 38). Interestingly,
Klingner and colleagues did not observe notable reductions in
thalamic coupling with frontal-striatal-cerebellar nodes in schiz-
ophrenia, reported by both aforementioned groups. There are at
least two possible interpretations for this difference: (i) the sam-
ple size in the Klingner study was much smaller and possibly
underpowered to find both sets of patterns (although the effect
size analysis and replication analyses by Anticevic and colleagues
argues against this possibility); and (ii) Klingner and colleagues
may have employed techniques, such as using GSR as a pre-
processing step, that could have led to different results (73). It
remains to be systematically determined what the true contri-
bution of the global signal is in these analyses, especially in the
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patient groups. One possibility is that the global signal carries
biologically meaningful information regarding cortical-thalamic
disruptions in schizophrenia that needs to be carefully charac-
terized. Methodological issues notwithstanding, this emerging
body of work strongly and consistently implicates disruptions in
thalamo-cortical information flow as a neural system marker in
schizophrenia.
While this initial progress in mapping thalamo-cortical distur-
bances in schizophrenia represents a promising advance in psychi-
atric neuroimaging research, there are still fundamental gaps in our
understanding of how such findings relate to neuropathological
mechanisms of this illness. There are a number of future directions
that the field should pursue to better understand these observa-
tions. For instance, it remains unknown why there are dissociable
disturbances across thalamic nuclei in schizophrenia. Future stud-
ies focused more exclusively on the medio-dorsal nucleus versus,
say, the pulvinar (known to be more involved in visual process-
ing) could begin to explain mechanism behind these differences.
Although the original study by Welsh and colleagues provides clues
here, follow-up studies with more power that focus on the medio-
dorsal nucleus could provide finer-grained information regarding
its patterns of dysconnectivity with the PFC.
Another complex issue that is not adequately resolved by any of
the noted investigations relates to medication effects. For instance,
there are considerations of medication dose, type of medications
(given that patients are often treated with multiple drugs from
different medication classes), and possible systematic differences
in the medications received by patients carrying the diagnoses
of schizophrenia, schizoaffective, and bipolar (e.g., mood stabi-
lizers and anti-depressants). While all studies address this issue
statistically to a certain extent (by computing chlorpromazine
equivalents and then co-varying for the medication dose), future
studies in un-medicated patients are needed. It is possible, how-
ever, that medication may not necessarily be a confound in this
case – instead, antipsychotic medication could actually stabilize
thalamo-cortical dysconnectivity. Studies explicitly aimed at test-
ing medication effects on connectivity could provide more detailed
insight into this issue. It also remains unknown if the identi-
fied patterns of large-scale thalamo-cortical dysconnectivity are
characteristic only of chronic stages of schizophrenia or whether
they already appear in the prodromal or early stages of the illness.
Establishing the link between identified thalamo-cortical dyscon-
nectivity and illness progression remains a vital effort to inform
the viability of this marker for predicting and/or tracking risk and
progression of the disease. While one of the studies noted above
provides a functional link between sensory-motor-thalamic over-
connectivity and PANSS symptoms, it remains unknown if these
patterns relate to cognitive and executive functional deficits char-
acteristic of the schizophrenia syndrome (26). It may be possible
that alterations in thalamo-cortical function (especially the PFC
component) in part relate to cognitive deficits observed in this
illness.
Additional questions still exist pertaining to the cross-
diagnostic relevance of these observations. As noted above, it was
shown by Anticevic and colleagues that qualitatively similar pat-
terns of thalamic dysconnectivity are apparent in bipolar illness
(although smaller in magnitude than those found in schizophre-
nia). It remains to be determined if those bipolar patients with a
history of co-occurring psychosis are quantitatively more similar
to alterations identified in schizophrenia (123). Such finer-grained
cross-diagnostic investigations have further potential to inform
and refine the clinical relevance of the identified marker. These
studies should be complemented with targeted efforts to improve
the classification provided by Anticevic and colleagues and allow
for even more precision in harnessing this putative biomarker.
Recently Fox and Greicius discussed progress in neuropsychiatric
studies using resting-state connectivity. They appropriately con-
cluded at the time that in schizophrenia there has been remarkably
little progress in producing replicable results (34), perhaps owing
to the complexity and heterogeneity of this neuropsychiatric illness
noted above. These recent studies reviewed here, which collectively
focused on identifying patterns of thalamo-cortical disruption
in schizophrenia, may be converging on a parsimonious final
common pathway of this complex disease, at least at the neural
systems level (43). In that sense, these effects may be one of the
better-replicated findings in the schizophrenia connectivity liter-
ature to date, offering promise for biomarker development and
refinement.
A longer-term goal will entail bridging this neural system-level
marker of schizophrenia with evolving cellular-level hypotheses
of schizophrenia neuropathology. It remains unknown how the
identified neural system-level markers relate to hypotheses that
propose disruptions at the cellular level in schizophrenia. For
instance, Anticevic and colleagues articulate a possible role of the
disruption in cortical excitation (E) and inhibition (I) balance
within the cortical microcircuit in producing system-wide disrup-
tions, which may occur in schizophrenia (see next section) and in
turn affect cognition (162). It remains unknown, however, how
such alterations can scale to produce the presently observed pat-
tern of aberrant thalamo-cortical connectivity. A corollary of this
hypothesis relates to observations in bipolar illness, which was
associated with an intermediate pattern of thalamo-cortical alter-
ations. In bipolar illness different cellular-level hypotheses have
been proposed from those hypothesized to occur in schizophrenia
(112, 163, 164) [although some authors have articulated shared
disturbances in GABA interneuron function (165)]. Therefore,
either distinct mechanisms operate in these different neuropsy-
chiatric conditions that converge on the same alterations or there
may be, at least in part, a shared alteration in some of the same
mechanisms across the two conditions. That is, it is possible that
some patients with bipolar illness share some of the features of
cellular neuropathology that affect patients with schizophrenia
(165), especially those bipolar patients who present with co-
occurring psychosis (166). Moreover, alterations along a number
of distinct neurotransmitter pathways, involving a confluence of
glutamate (7, 167), GABA (19), and dopamine disturbance (106),
could jointly converge on a profound disturbance in thalamo-
cortical function. In the upcoming sections, we discuss additional
neuroscientific tools, namely pharmacological neuroimaging and
computational modeling, which can be combined to help elucidate
the role of specific cellular and synaptic mechanisms in observed
system-level disruptions that occur in schizophrenia.
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PHARMACOLOGICAL NEUROIMAGING – TOWARD A
MECHANISTIC UNDERSTANDING OF SYSTEM-LEVEL
DISRUPTIONS IN PSYCHIATRIC ILLNESS
We presented evidence, supported by several emerging studies,
for profound alterations in thalamo-cortical information flow in
schizophrenia, as well as evidence for alterations in PFC connec-
tivity. Yet, the mechanisms that could inform rationally guided
pharmacotherapy for these disturbances in schizophrenia remain
unknown. One leading mechanistic hypothesis proposes possi-
ble disruptions in the E/I balance in the cortical micro-circuitry
resulting from hypo-function of the NMDAR (7), which might
affect cortical computations, leading to large-scale dysconnectivity
(14). A way to link such pharmacological mechanisms to neural
system-level observations is to directly compare clinical patient
studies and results following pharmacological manipulations, or
to separately test the effects of pharmacological manipulations in
healthy volunteers.
A powerful candidate approach is to use ketamine, a non-
competitive NMDAR antagonist and a leading schizophrenia
pharmacological model, which transiently, reversibly, and safely
induces characteristic schizophrenia symptoms in healthy volun-
teers (7). Here pharmacological manipulations provide a method
with which researchers can test the effects of a given neuro-
transmitter perturbation in a constrained, causal, and hypothesis-
driven way. Moreover, such synaptic hypotheses can be imple-
mented directly into computational models to generate experi-
mental predictions (discussed in the last section). A prevailing
hypothesis regarding ketamine’s effects on cortical micro-circuitry
proposes preferential antagonism of interneurons with subsequent
disinhibition of pyramidal cells (168), a mechanism we imple-
mented in a recent computational modeling investigation (58)
(see below for a discussion). As an extension of this hypothesis, a
cortex-wide disruption in E/I balance might de-stabilize thalamo-
cortical information flow in ways observed in schizophrenia (or
other neuropsychiatric conditions). It should be noted that it still
remains unclear what the relative contribution is of NMDARs
on pyramidal cells (169) versus interneurons (58) may be in
relation to the hypothesized alterations in E/I balance. Under-
standing the relative contribution of such cell-specific receptor
alterations remains an important future direction, which could
inform targeted pharmacotherapies. Such detailed studies of how
cellular-level alterations could give rise to thalamo-cortical alter-
ations following pharmacological manipulations remain to be
done. Nevertheless, there is emerging evidence from a few focused
investigations detailing the effects of ketamine on large-scale cor-
tical connectivity. These investigations provide preliminary clues
for how ketamine’s effects on large-scale systems may resemble
effects seen in schizophrenia.
For instance, a recent resting-state connectivity study by
Driesen and colleagues investigated the effects of acute ketamine
administration to healthy volunteers on large-scale global cor-
tical connectivity (Figure 4A). The authors use a resting-state
connectivity approach similar to that applied by Cole and col-
leagues in chronic schizophrenia (40), extended to include the
entire brain (i.e., all voxels without imposing a PFC restriction).
A number of studies have demonstrated that NMDAR antagonist
administration is associated with excessive pyramidal cell activity,
increases extracellular glutamate levels (16), and increases in per-
fusion and cortical metabolism (48–51, 53). A logical extension of
this hypothesis is that administration of ketamine may profoundly
affect large-scale cortical connectivity. Consistent with pre-clinical
studies, Driesen and colleagues found that NMDAR antagonist
administration resulted in a global elevation of functional connec-
tivity (i.e., everywhere in the brain). This observation is broadly
consistent with cellular-level hypotheses of ketamine’s effects on
glutamate release, which may increase coupling of cortical cir-
cuits at rest by increasing the E/I ratio (i.e., decreasing cortical
microcircuit inhibition). It is, however, critical to point out that
chronic schizophrenia has typically been associated with reduc-
tions in cortical connectivity (170) and activation (70), especially
in the PFC (11), as described above. Therefore, there are at least
some evident discrepancies between the effects of pharmacological
models such as ketamine and the actual illness (54). This impor-
tant discrepancy between ketamine’s effects on PFC circuits and
observations in schizophrenia should be reconciled in prospective
studies that directly compare pharmacological and clinical effects
using resting-state connectivity measures. One possible factor that
could explain differences between NMDAR antagonist effects and
chronic schizophrenia is that such pharmacological models may
be relevant only to specific patient subgroups or illness stages.
One possibility is that the increased connectivity under ketamine
is similar to the early stages of psychotic illness. This hypothesis
is consistent with elevated glutamate levels reported early in the
illness course (113, 171). It is also consistent with the observation
that ketamine tends to produce symptoms associated with incip-
ient illness stages, rather than auditory hallucinations that occur
in frank psychosis and chronic schizophrenia (15, 49, 172–174).
Moreover, significant functional dynamical changes may occur
during schizophrenia progression (46) that could profoundly
affect PFC function, structure, and integrity. This hypothesis is
supported by recent meta-analytic findings reporting decreases
in glutamate across the illness progression (113). Whether such
alterations across the schizophrenia illness course are reflected
in PFC connectivity changes remains unknown, as does keta-
mine’s impact on PFC functional network architecture. Future
pharmacological studies as well as cross-sectional and longitu-
dinal clinical investigation are needed to test this hypothesis. In
addition, careful pre-clinical experiments could possibly inform
such hypotheses (118).
A complementary area of research has investigated the effects of
ketamine on functional connectivity (177) in relation to its poten-
tial anti-depressant effects (178). While a comprehensive treat-
ment of anti-depressant effects of ketamine is beyond the scope
of this review, it is important to note that studies examining its
effects on glutamateric pathways in the context of mood symptoms
(178) may be highly informative for developing our understanding
of its relevance to schizophrenia (111). Briefly, emerging models
in this area postulate that ketamine may act as anti-depressant
by promoting synaptic plasticity via intra-cellular signaling path-
ways, ultimately promoting brain-derived neurotrophic factor
expression via synaptic potentiation (179) and in turns synap-
tic growth (178). In that sense, acute NMDAR antagonism may
promote synaptic plasticity along specific pathways impacted in
mood disorders, such as ventral medial PFC (180, 181, p. 916).
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FIGURE 4 | Characterizing connectivity alterations using
pharmacological neuroimaging. While functional connectivity neuroimaging
alone has been a powerful tool for characterizing neural system-level
alterations in schizophrenia, it is ultimately a correlational tool. That is, we are
examining alterations in the associations as a function of illness presence or
absence. To move toward understanding the possible role of specific
neurotransmitter mechanisms in schizophrenia, however, neuroimaging
studies can be combined with pharmacological manipulations (47, 175). Such
causal experimental manipulations can shed light on the role of specific
neurotransmitter systems in schizophrenia (15). (A) Driesen and colleagues
have shown that administration of ketamine profoundly altered the global
connectivity of the brain. Specifically they demonstrated that the GBC
measure increased following ketamine administration, possibly reflecting a
hyper-glutamatergic state or a state of cortical disinhibition (54) consistent
with animal models (111, 176). Formal computational models are needed in
order to provide a deeper intuition for such pharmacological effects on
large-scale neural systems. (B) Anticevic and colleagues have shown that
administration of an NMDAR antagonist, ketamine, alters the connectivity of
large-scale anti-correlated neural systems during performance of a working
memory task (18). Although this connectivity study was performed during
task performance rather than rest, it illustrates a proof of concept for how a
pharmacological challenge can alter connectivity in a causal way. Note: figures
adapted with permission from Driesen and colleagues (54) and Anticevic and
colleagues (18).
Conversely, when administered to patients diagnosed with schiz-
ophrenia, NMDAR antagonists seem to worsen their symptom
profile (182), perhaps by “pushing” an already aberrantly elevated
glutamatergic signaling profile upward. Collectively such dissocia-
ble effects of ketamine may imply that along distinct circuits there
may be an inverted-U relationship between ketamine’s effects and
symptoms: depressed patients may be positioned on the low end of
the inverted-U (178) and schizophrenia patents may be positioned
on the higher end (183). Both task-based and resting-state func-
tional connectivity techniques are well positioned to interrogate
such system-level effects of NMDAR antagonists in humans.
As an example of such an approach, another study examining
the effects of ketamine by Anticevic and colleagues focused on
understanding the functional impact of NMDAR antagonism on
the organization of the large-scale, anti-correlated neural systems
(Figure 4B). This pharmacological neuroimaging investigation
was explicitly focused on understanding ketamine effects on WM.
However, in the context of this cognitive question, Anticevic and
colleagues also assessed whether the task-based functional con-
nectivity of large-scale neural systems is affected by ketamine
administration. As we noted above, such task-based connectivity
approaches can be useful to pinpoint how large-scale systems are
affected during specific cognitive operations. The authors found
that an acute administration of a low ketamine dose profoundly
altered the typically observed anti-correlated structure of the large-
scale neural systems – namely the task-positive fronto-parietal
regions (184) and the task-negative regions (typically termed the
default-mode network, DMN) (28). In line with this observed
decrease in functional connectivity, Driesen and colleagues (185)
also found a reduction in WM task-based functional connectivity
along fronto-parietal areas (when using a DLPFC seed) follow-
ing ketamine administration. The investigators reported increased
functional connectivity of the DLPFC during rest using the exact
same seed. This set of observations in particular sheds light on
how a pharmacological manipulation such as NMDAR antago-
nism may have profoundly different effects in the context of a
cognitive task (e.g.,WM) and during rest. The mechanisms behind
this observed difference are beyond the scope of this review and
will be discussed in forthcoming studies.
Briefly, it may be possible that large-scale, network-level syn-
chrony during WM is critically dependent on appropriate content-
specific signals between neural subpopulations (186). In contrast,
the BOLD fluctuations during rest likely relate to coupling between
regions at the infra-slow-frequency ranges (187). It may be pos-
sible that a reduction in appropriate task-evoked synchrony by
NMDAR antagonism reduces the ability of a network to form a
coherent and optimal level of functional connectivity during WM.
This may be exacerbated by an amplification of shared “noise” in
the system, which is reflected in the apparent hyper-synchrony
at rest (54). Collectively, therefore, an NMDAR antagonist may
“disinhibit” the system, which gives rise to infra-slow, spatially
distributed fluctuations across large areas of cortex that manifest
in aberrant hyper-connectivity at rest. Precisely due to this ele-
vated background noise, in combination with disrupted capacity
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for appropriate task-evoked synchrony, the net effect during WM
may be a reduction in functional connectivity (which contrasts
with observations at rest). Moreover, task-evoked activity can
suppress the slow fluctuations associated with rest (188); if this
suppression were weakened in schizophrenia, the“signal-to-noise”
ratio would be degraded and task-based functional connectivity
could be reduced. Because task-based and resting-state synchrony
may be separated by timescale, EEG studies, combined with fMRI,
could potentially address such hypotheses (189–191). Moreover,
precisely because of such important differences between task and
rest in certain contexts (e.g., ketamine manipulation) it remains
important for task-based and resting-state investigations to inform
one another. In the upcoming section, we explicitly discuss the
recent developments in computational modeling that can provide
a platform for formal integration of neuroscience theory both in
the context of resting-state studies as well as formal task-based
experiments.
BRIDGING LEVELS OF ANALYSIS VIA COMPUTATIONAL
MODELING
Above we discussed recent clinical and pharmacological neu-
roimaging findings that shed light on the nature of large-scale
neural system alterations in schizophrenia. In particular, the phar-
macological experiments provide a causal method to explicitly
manipulate specific neurotransmitter mechanisms that may be
involved in schizophrenia. In that sense, these studies can begin
to address given neurotransmitter contributions to neural system-
level and behavioral alterations observed in schizophrenia. Still,
these studies cannot measure synaptic and cellular-level phe-
nomena alone. Therefore, one possible methodological integra-
tion involves a formal link between such pharmacological/clinical
experiments and computational models that contain this level
of functional detail. One branch of computational model that
provides a particularly productive platform involves biophysically
based models that contain the relevant synaptic mechanisms (57,
192) thought to be disrupted in neuropsychiatric illness (55). Such
microcircuit models have been already harnessed to make predic-
tions in the context of ketamine experimental manipulations of
WM (58) (discussed more below). There is, however, an ongoing
need to scale such models to the level of neural systems to provide
relevant predictions for both resting-state and task-based clinical
and pharmacological studies.
Recent computational models have been developed to explic-
itly capture how the global pattern of resting-state functional
connectivity arises through cortico-cortical interactions (193). In
particular, modeling studies in this area have focused on the extent
to which functional connectivity can be predicted by long-range
anatomical connectivity (Figure 5A). The dynamic interactions
between neural populations will also shape functional connec-
tivity. The starting point for these models is an anatomical cou-
pling matrix reflecting long-range connections between cortical
regions, derived either from tracer studies in macaque monkeys
or from diffusion tractography in humans. The activity of a local
region (a node in the large-scale network) follows some dynam-
ics and is shaped by input from other areas, propagating via the
long-range connections. Ongoing activity, either due to chaos or
noise, produces fluctuations in the activity across the network.
The functional connectivity of the model can then be calculated
and compared to functional connectivity observed in experiments.
Honey and colleagues (194) studied long-range chaotic synchro-
nization when local nodes follow oscillatory dynamics, using con-
nectivity from human diffusion tractography. They found that
the global dynamics of the network could partially explain the
presence of strong functional connections between regions that
lack direct anatomical connection. Cabral and colleagues (195)
used a similar oscillatory model with connectivity data from
healthy subjects, and parametrically varied the overall strength of
long-range connections. They found that decreasing long-range
connection strength altered functional connectivity patterns in
a manner similar to those observed in schizophrenia (9), with
reduced overall functional connectivity strength and changes in
certain graph-theoretic measures of the functional connectivity
matrix.
Deco and colleagues (59, 193) extended this approach, deriving
long-range connectivity from human diffusion tractography and
implementing the local node dynamics with a biophysically based
model of a cortical microcircuit. In particular, the local micro-
circuit incorporates recurrent excitation with realistic synaptic
dynamics, and the strength of recurrent excitation enables multi-
stable dynamics that can subserve cognitive computations such
as WM (197, 198). Noisy background inputs to nodes induce
fluctuations in activity that are shaped into correlated patterns
by long-range coupling between nodes through the anatomi-
cally derived connectivity. Functional connectivity in the model is
given by the pattern of these correlated fluctuations. The authors
parametrically varied two global parameters with biophysical rel-
evance: the strength of recurrent excitation within local nodes,
and the strength of long-range connections between nodes. The
strengths of local and long-range connections combine to pro-
vide recurrent excitation in the network. They found that the
similarity between model and experimental functional connec-
tivity patterns was maximized when the network’s baseline state
is near the boundary in parameter space between stability and
instability induced by excess excitation. These studies reveal that
the pattern of functional connectivity in the model is sensitive to
both the pattern of anatomical connectivity and the physiologi-
cal parameters that scale local and long-range connections. The
biophysical basis of these models makes them directly applicable
to address the dynamical consequences of anatomical and physi-
ological changes induced by disease processes or pharmacological
manipulation. Changes in the strengths of local and long-range
connections may induce differential effects in the patterns of
functional connectivity. Therefore, fitting models to functionally
connectivity in patients could distinguish among distinct synaptic
alterations. This approach could also potentially reveal the effects
of complex drug actions on local circuit tuning and long-range
interactions.
The models described above were explicitly constructed to
simulate resting-state fluctuations, rather than to implement a
particular function such as WM. Nevertheless, functional mod-
els can still make predictions that can be tested using functional
connectivity, especially task-based functional connectivity (81). To
this end, Anticevic and colleagues extended a microcircuit model
of WM to study interactions between large-scale networks and
Frontiers in Psychiatry | Schizophrenia December 2013 | Volume 4 | Article 169 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anticevic et al. Connectivity, pharmacology, and computation in schizophrenia
FIGURE 5 | Computational modeling of system-level effects via
biophysically realistic computational approaches. While detailed
microcircuit models have made an impact on our understanding of cortical
dynamics (56), the challenge remains to scale such models to incorporate
dynamic interactions across large-scale neural systems, which are likely
profoundly affected in schizophrenia (and other severe neuropsychiatric
conditions). (A) A recently published elegant study by Deco and colleagues
(59) illustrates an approach where a biophysically realistic model of cortical
computations has been applied to understand the generation of
slow-frequency fluctuations in the BOLD signal. The authors used
diffusion-spectrum imaging to anatomically constrain the model and in turn
fitted the modeling results to empirically-derived resting-state functional
connectivity data. The result illustrates that coherent fluctuations in the
BOLD signal (i.e., resting functional connectivity) may emerge from a
system that is at the edge of chaos, allowing linear but transient departures
in neuronal firing rates. (B) Anticevic and colleagues have used a functional
model of working memory, a cognitive process that is profoundly affected in
schizophrenia (26), to better understand the role of NMDA receptor function
in the interaction of large-scale anti-correlated neural systems. Specifically
they studied the functional antagonism present during a cognitive task
between the task-activated (fronto-parietal module) and task-deactivated
(default-mode module) networks (196). Following a complete parameter
sweep (left), the authors found that a small perturbation of the NMDARs on
inhibitory interneurons within each cortical microcircuit captured the firing
that was observed experimentally following ketamine administration in
healthy volunteers (18). Collectively, these studies offer examples for how
biologically constrained modeling approaches can be applied to understand
large-scale neural system physiology in both resting-state (non-functional)
and task-based (functional) settings. Note: (A) of the figure was adapted
with permission from Deco and colleagues (59).
their disruption by synaptic perturbation (Figure 5B) (18). The
biophysically based model consists of two modules of spiking
microcircuits: one that is task-activated and capable of WM com-
putations, and one that is task-deactivated from a high-activity
baseline state (hypothesized to model the activity pattern of the
default-mode network in the context of cognitive activation).
The interactions between these modules are mutually suppres-
sive, via long-range projections onto inhibitory interneurons,
a feature founded on findings of anti-correlated fluctuations
between task-positive and default-mode networks (30). Within
the model authors specifically studied the functional impact
of disinhibition via NMDA hypo-function on interneurons, to
relate such microcircuit hypotheses to neural changes observed
under ketamine administration. The authors found that disinhi-
bition of the entire network results in a failure to shut off the
default-mode module, impairing the pattern of activation and
deactivation during WM tasks. This modeling study provides
one example of how a microcircuit model of a specific cogni-
tive process (i.e., WM) can be scaled to incorporate system-level
interactions and make predictions relevant for task-based func-
tional connectivity. In addition, one strength of computational
models is the ability to systematically explore different oper-
ating regimes in the space of model parameters. For example,
Anticevic and colleagues contrasted reductions in recurrent excita-
tion onto interneurons versus pyramidal cells, generating testable
predictions for elevated versus reduced excitation/inhibition bal-
ance. As a test of the model architecture and operation, the
authors analyzed task-based functional connectivity between task-
activated and task-deactivated networks, computed across trials
during the delay period of a WM task. Under control conditions,
the two networks exhibited robust negative correlation, in line
with effective antagonistic interactions in the model. In contrast,
under ketamine administration this negative correlation disap-
pears (Figure 4B), in line with the model prediction that the
task-positive module cannot effectively suppress the hyperactive
default-mode module. Collectively, this study provides prelim-
inary evidence that functional models can be directly related
to functional connectivity predictions in the context of WM.
Future computational/experimental studies should be designed
to extend this framework to more complex processes and symp-
toms that may be disrupted in schizophrenia. We argue that such
ongoing efforts for the integration of theory, pharmacological
experiments and clinical work will be a vital path for the field
of clinical neuroscience to provide testable and rationally guided
advances for understanding disease mechanisms and putative
treatments.
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CONCLUDING REMARKS
Collectively, we articulated recent focused developments in three
areas of clinical neuroscience of schizophrenia: (i) we reviewed
methodological advances in resting-state functional connectivity
that were directly translated to understand neural system-level
disturbances in schizophrenia. We specifically focused on data-
driven techniques that offer a promising way to detect disrupted
connectivity while bypassing the likely complexity and regional
heterogeneity of network alterations that are present in schizo-
phrenia. We also discussed ongoing developments in studies of
thalamo-cortical dysconnectivity in schizophrenia that are directly
informed by influential theoretical models of the illness. (ii) We
highlighted select pharmacological studies of the NMDARs that
offer a causal way to understand neural system alterations in
psychiatric illness. (iii) We articulated the developments in bio-
physically based computational modeling studies that provide
a platform for testing specific synaptic alterations. In turn, we
demonstrate that such models can potentially be scaled to the level
of neural systems to make relevant predictions for both resting-
state or task-based connectivity experiments. We argue that the
ongoing blend of these three approaches can provide advances in
the field of clinical neuroscience that create a final output that is
much greater than the sum of its parts.
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